Editor's Corner

The new biotech report from Ernst & Young underscores just how vibrant the US biotech industry is. Its ability to attract record sums of investment dollars speaks volumes about the innovation and activity we see in this country. In Europe, where regulators have posed big challenges to drug makers, the scene is much more problematic, as anyone tracking the IPO market would be quick to agree. It's Asia, with its well educated, globally wired work force, that will present some of the biggest competitive challenges to the US. Countries like India and China also offer a new source of energetic development partners, and that will be a boon for the world. - John Carroll

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.